collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech company, and US generic drug major Watson Pharmaceuticals (NYSE: WPI) to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar versions of several biological drugs.
Under the terms of the deal, Amgen will assume primary responsibility for developing, manufacturing and initially commercializing the oncology antibody products. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe .Register here
Under the terms of the deal, Amgen will assume primary responsibility for developing, manufacturing and initially commercializing the oncology antibody products. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe .Register here
No comments:
Post a Comment